标准治疗与Plasmalyte在儿童登革休克综合征中的比较(SPLID试验):一项开放标签随机对照试验的研究方案
本研究为在印度北部三级医院开展的三臂、前瞻性、开放标签、平行组随机对照试验,计划36个月内纳入135例2月龄至18岁符合WHO分类的登革休克综合征患儿。患儿按1:1:1随机接受生理盐水、乳酸林格液或Plasmalyte复苏,主要结局为随机化后48小时内血清氯升高≥5 mmol/L。
要点
- 比较生理盐水、乳酸林格液与Plasmalyte在儿童登革休克综合征中的复苏效果。
- 主要结局为48小时内血清氯升高≥5 mmol/L。
- 次要结局包括酸碱状态、住院时间、胶体需求、急性肾损伤、器官功能障碍和死亡。
核心结论
- 该试验旨在确定标准治疗与Plasmalyte在液体复苏后48小时内血清氯变化方面的差异,并比较酸碱状态、住院时间、新发急性肾损伤、器官功能障碍和死亡。
研究设计与样本
- 三臂、前瞻性、开放标签、平行组随机对照试验,在印度北部三级医院开展,为期36个月。
- 计划招募135例2月龄至18岁符合WHO分类的登革休克综合征患儿,按1:1:1随机分配接受生理盐水、乳酸林格液或Plasmalyte。
- 同时进行意向性分析和符合方案分析。
关键数值与推荐
- 主要结局为随机化后48小时内血清氯升高≥5 mmol/L。
- 次要结局包括酸碱状态变化、住院时间、需要胶体推注、新发急性肾损伤、器官功能障碍和死亡。
- 急性肾损伤按KDIGO标准定义,器官功能障碍按PELOD-2评分定义。
- 试验期间发生的任何严重不良事件将在24小时内报告伦理委员会和监测委员会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous fluid resuscitation is the first-line therapy in the management of dengue shock syndrome (DSS), a severe complication of dengue fever characterized by vascular leakage and organ dysfunction. However, the choice of intravenous fluids for resuscitation in DSS remains contentious. Evidence is lacking with regard to standard therapy, like normal saline (NS) and Ringer lactate (RL), versus newer balanced crystalloids like Plasmalyte (PL) for resuscitation of DSS. METHODS: This study is a three-arm, prospective, open-label, parallel-group randomized clinical trial (RCT) to be conducted at a tertiary care hospital in north India over 36 months. We will recruit 135 children aged 2 months to 18 years, admitted with DSS who fulfill the eligibility criteria as per the WHO classification. The participants will be randomized to receive NS, or RL or PL in a 1:1:1 assignment. The primary outcome is a ≥5 mmol/L increase in serum chloride within 48 h post-randomization. The secondary outcomes include changes in acid-base status, hospital stay, need for colloid bolus, new-onset acute kidney injury (AKI), organ dysfunction, and mortality. AKI and organ dysfunction will be defined as per KDIGO criteria and Pediatric Logistic Organ Dysfunction 2 score (PELOD-2), respectively. Any serious adverse event occurring during the course of the trial will be reported to the ethics committee and the monitoring committee within 24 h. Both intention-to-treat and per-protocol analyses will be conducted. DISCUSSION: DSS initially requires prompt fluid resuscitation with crystalloids. NS in large volumes may lead to hyperchloremic metabolic acidosis. RL, containing lactate as a buffer, is contraindicated in children with compromised liver function due to their reduced ability to metabolize lactate. PL, a balanced crystalloid, is isotonic with a chloride concentration similar to that of plasma. Thus, the RCT aims to determine the change in serum chloride between standard treatment vs. PL within 48 h of fluid resuscitation and to compare the change in acid-base status, hospital stay, new-onset AKI, organ dysfunction, and mortality in children with DSS. TRIAL REGISTRATION: The SPLID trial has been registered prospectively with the Clinical Trial Registry of India (CTRI) registry no. CTRI/2023/11/060213 [Registered on 23/11/2023].
引用
- Mahajan V, Shah NS, Vasudeva T, et al. Standard Therapy versus Plasmalyte in Children with Dengue Shock Syndrome (SPLID trial): a study protocol for an open-labeled randomized control trial. Trials. 2026. PMID: 41923109. doi:10.1186/s13063-026-09630-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。